Opportunity
Federal Register #2026-13480
NCI Seeks Partners for Licensing and Co-Development of Novel Cancer and Infectious Disease Therapeutics
Buyer
National Cancer Institute
Posted
July 02, 2026
Identifier
2026-13480
NAICS
541714, 541715, 325414
The National Cancer Institute (NCI), part of the Department of Health and Human Services, is seeking partners for licensing and co-development of two government-owned therapeutic innovations: - Government Buyer: - Department of Health and Human Services - National Cancer Institute (NCI) - Technology Transfer Center - Products/Technologies Offered: - Nucleic acid-based vaccine for human T-cell leukemia virus type I (HTLV1) - Part number: E1262022 - Preclinical stage - Designed to generate virus-like particles using HTLV1 Env and gag proteins - Intended for prevention of HTLV1 infection and related diseases (e.g., adult T-cell leukemia/lymphoma, HAM/TSP) - Conserved viral peptide (CE1)-based immunotherapy for hepatocellular carcinoma (HCC) - Part number: E0232024 - Discovery stage - Elicits T cell response against HCC cells - Potential uses: immunotherapy, vaccine, predictive biomarker, patient stratification - Unique/Notable Requirements: - Both technologies are in early (preclinical/discovery) stages - NCI seeks research co-development partners and/or licensees for further development and commercialization - No specific commercial OEMs or vendors are named; technologies are government-owned - Focus on addressing unmet needs in oncology and infectious disease
Description
The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics aimed at the prevention and treatment of hepatocellular carcinoma (HCC). The CE1 peptide has been identified as a common epitope that elicits a T cell response against HCC cells and shows potential as an immunotherapy, including a vaccine. This opportunity focuses on developing novel treatments for HCC, a leading cause of cancer-related death worldwide with limited current therapeutic options. The NCI invites collaboration for licensing and co-development of this therapeutic technology.